STOCK TITAN

Kalvista Pharm - KALV STOCK NEWS

Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.

KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.

Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.

Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.

Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.

Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) will participate in the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on protease inhibitors and offers a webcast of the presentation on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. granted nine newly-hired employees inducement options to purchase 65,000 shares of KalVista common stock. The options have an exercise price of $11.40 per share and vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. presented data at the 2024 HAEi Regional Conference Americas highlighting the negative impact of treatment delays on hereditary angioedema (HAE) patients. These delays lead to increased anxiety, quality of life issues, and suboptimal clinical outcomes, affecting both on-demand and prophylaxis patients. The company aims to address these challenges with sebetralstat, potentially improving compliance with treatment guidelines and enhancing disease control for HAE patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
Rhea-AI Summary
KalVista Pharmaceuticals receives Promising Innovative Medicine designation from UK MHRA for sebetralstat, an oral plasma kallikrein inhibitor for hereditary angioedema treatment, allowing early patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the Phase 3 KONFIDENT clinical trial for sebetralstat, a potential first oral on-demand therapy for hereditary angioedema. The trial met all endpoints, demonstrating a favorable safety profile. The company closed a successful underwritten offering, appointing Benjamin L. Palleiko as the new CEO. Financially, the company reported no revenue for the quarter, with increased R&D and G&A expenses leading to a net loss of $29.0 million. Cash position decreased to $75.6 million as of January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the acceptance of multiple abstracts at the 2024 HAEi Regional Conference, showcasing research on hereditary angioedema treatment patterns and patient perceptions. The company is a Silver-level sponsor of the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences
Rhea-AI Summary
KalVista Pharmaceuticals appoints Benjamin L. Palleiko as CEO to lead the transition to a commercial entity with sebetralstat for HAE. NDA filing on track for H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
management
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12th, 2024. The company focuses on oral protease inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. granted seven newly-hired employees inducement options to purchase 43,000 shares of KalVista common stock. The options have an exercise price of $14.14 per share and vest over a four-year period, subject to continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Rhea-AI Summary
KalVista Pharmaceuticals presented real-world data revealing treatment delays, suboptimal outcomes, and anxiety linked to injectable treatments for Hereditary Angioedema (HAE) patients at AAAAI 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
none
Kalvista Pharm

Nasdaq:KALV

KALV Rankings

KALV Stock Data

571.23M
44.06M
1.36%
113.48%
11.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE